# A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD)

> **NCT07748403** · PHASE1,PHASE2 · RECRUITING · sponsor: **Prime Medicine, Inc.** · enrollment: 42 (estimated)

## Conditions studied

- Wilson Disease
- Wilson's Disease
- Wilsons Disease

## Interventions

- **DRUG:** PM577a

## Key facts

- **NCT ID:** NCT07748403
- **Lead sponsor:** Prime Medicine, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2028-11
- **Final completion:** 2028-12
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07748403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07748403, "A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07748403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*